Recurrence of Esophageal Achalasia After Treatment
Yes, esophageal achalasia can recur after treatment, with up to one-third of patients experiencing symptom recurrence within 4-6 years of initial treatment. 1
Recurrence Rates by Treatment Modality
Pneumatic Dilation (PD)
- Initial success rate: 90% in first year, decreasing to 86% in second year 1
- Long-term recurrence: Up to one-third of patients experience symptom recurrence during 4-6 years of follow-up 1
- With repeat dilations: Success rates can reach 97% at 5 years and 93% at 10 years 1
- Very long-term outcomes: 100% of patients initially treated with PD eventually required myotomy in one study with 17.5-year follow-up 2
Laparoscopic Heller Myotomy (LHM)
- Lower recurrence rate compared to PD: 47.3% vs. 100% over long-term follow-up (10-40 years) 2
- Timing of recurrence after myotomy:
Per-Oral Endoscopic Myotomy (POEM)
- Short-term efficacy: 89-97% in multiple large case series 1
- Long-term data: Still limited as POEM is a newer procedure 1
- Particularly effective for type III achalasia compared to other treatments 4
Mechanisms of Recurrence
Inadequate initial treatment:
Progressive disease:
Treatment complications:
Management of Recurrent Achalasia
After initial PD:
After initial myotomy:
Post-treatment monitoring:
Treatment Selection for Recurrent Disease
- Type I and II achalasia: Both repeat PD and surgical options are effective 4
- Type III achalasia: POEM may be particularly advantageous due to ability to perform longer myotomy 1, 4
- Presence of megaesophagus: May require more aggressive intervention 7
Important Caveats
- Most patients with achalasia will require multiple procedures over their lifetime to maintain symptom control 2
- The risk of progression to end-stage achalasia exists despite treatment 2
- Post-treatment reflux requires monitoring and management with PPIs 1
- Treatment should be performed at centers with expertise in achalasia management 1, 4
In summary, while initial treatment success rates are high for achalasia, recurrence is common across all treatment modalities, with the highest rates seen after pneumatic dilation and lowest after surgical myotomy. Most patients will require additional interventions throughout their lifetime to maintain symptom control.